Tranzyme Pharma Says That First Phase 3 Pivotal Trial Of Ulimorelin Failed

RELATED NEWS

Tranzyme Q4 Loss Narrows - Quick Facts

Trade TZYM now with

3/12/2012 5:34 AM ET

Late-stage biopharmaceutical company Tranzyme Pharma (TZYM: Quote), on Monday, along with specialty pharmaceutical company Norgine B.V., announced top-line results of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating ulimorelin.

The company stated that the trial failed to meet its primary and secondary efficacy endpoints.

Tranzyme further stated that the results of ULISES 007 showed that ulimorelin, at both 160 and 480 micrograms/kg doses, was not statistically different from placebo for the primary endpoint.

"These results are surprising and disappointing. While we are still planning to analyze the data from the second phase 3 trial ULISES 008, which we expect by the end of the second quarter, we are stopping all other NDA activities for ulimorelin," said Vipin K. Garg, Ph.D., President and Chief Executive Officer, Tranzyme Pharma.

Click here to receive FREE breaking news email alerts for Tranzyme Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 190 Articles

Editors Pick

Autodesk Results Miss Estimates; Cuts Outlook

Design software maker Autodesk, Inc. (ADSK) Thursday reported a 30 percent decline in earnings from last year, hurt by lower revenue and weaker margins. The company's quarterly earnings per share, excluding items, came in below analysts' expectations as did its quarterly revenue. At the same time,...

Dell Profit Drops 79% On Sluggish PC Demand

Struggling PC maker Dell Inc. said Thursday after the markets closed that its first quarter profit dropped 79% from last year, as revenue declined and margins deteriorated amid sluggish demand for personal computers. The company's quarterly earnings per share, excluding items, also came in way below analysts' expectations, but its quarterly revenue beat analysts' forecast.

Cisco Results Top Estimates

Cisco Systems, Inc., the world's largest computer networking gear maker, said Wednesday after the markets closed that its third quarter profit rose 14.5% from last year, helped by higher sales and a tax benefit. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly sales.